Filter results
You can narrow down the results using the filters
Publication type
Health topics
Conditions and diseases
Year
7997 results
-
Coronavirus (COVID-19) common operating picture – 27 January 2023
This infographic issued on 27 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia. -
Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations for consumers
This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers. -
Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations
This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations. -
Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations for consumers
This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers. -
Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations
This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations. -
Life Saving Drugs Program – Gaucher disease – Review summary and expert panel recommendations for consumers
This Gaucher disease review considered 3 enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health. -
Life Saving Drugs Program – Gaucher disease – Review summary and expert panel recommendations
This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations. -
My Aged Care – Service and Support Portal User Guide Part 1 – Administrator Functions
This user guide explains to administrators how to use the My Aged Care service and support portal. -
Government Provider Management System – Terms of use
This document outlines the terms of use for the Government Provider Management System (GPMS). The GPMS allows aged care service providers to see their Star Ratings. -
National Health and Medical Research Council – Projects funded
A list of National Health and Medical Research Council (NHMRC) projects and the committed funding. -
Evaluation of the COAG Section 19(2) Exemptions Initiative – Improving Access to Primary Care in Rural and Remote Areas Final Report
Evaluation of the COAG Section 19(2) Exemptions Initiative – Improving Access to Primary Care in Rural and Remote Areas Final Report -
Department of Health and Aged Care organisational chart
This chart shows the structure of the Department of Health and Aged Care, including our divisions, branches, statutory office holders and high priority taskforces. -
National Aged Care Advisory Council communique – December 2022
The meeting of the National Aged Care Advisory Council was held on 15 December 2022. -
Council of Elders communique – 8 and 9 December 2022
An update from the Council of Elders after their meeting on 8 and 9 December, 2022. -
AskMBS advisory – Established clinical relationship – Clarification of exemptions
Information and advice for general practitioners and other medical practitioners about the COVID-19 MBS telehealth ‘established relationship’ requirement, including a clarification of exemptions. -
Key updates for Aboriginal and Torres Strait Islander communities – 23 January 2023
This newsletter provides key health updates for Aboriginal and Torres Strait Islander households, communities and stakeholders. -
Commencement of new prescribed pattern of services – 30/20 telephone rule
Information on the new prescribed pattern of service 30/20 telephone rule, including relevant telephone attendance services. From 1 October 2022, GPs, Other Medical Practitioners and consultant physicians that claim relevant Medicare telephone items will be subject to the new rule. -
Final migration of missing CHSP clients – FAQs
This document answers some frequently asked questions the department has received from Commonwealth Home Support Programme (CHSP) service providers about Missing CHSP Client Migration process. -
Japanese encephalitis virus infection – Surveillance case definition
This document contains the surveillance case definition for Japanese encephalitis virus infection, which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case. -
CDBS – Substantiating dental services provided under the schedule
This guideline can help you to substantiate Child Dental Benefits Schedule (CDBS) services that you have claimed or that have been claimed through your provider number. You must also show that consent to dental services and costs has been obtained and recorded. -
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations. -
Life Saving Drugs Program – MPS I – Review summary and expert panel recommendations for consumers
This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers. -
Life Saving Drugs Program – MPS I – Review summary and expert panel recommendations
This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations. -
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer -
Exposure draft and explanatory statement – Aged Care Legislation Amendment (Governance and Reporting for Approved Providers) Principles 2022
This is an exposure draft of the proposed amendments to the Accountability Principles 2014 and Records Principles 2014 and the explanatory statement for these amendments. These amendments will support better provider governance and reporting arrangements.